|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DSTN |
Gene summary for DSTN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DSTN | Gene ID | 11034 |
| Gene name | destrin, actin depolymerizing factor | |
| Gene Alias | ACTDP | |
| Cytomap | 20p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | P60981 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11034 | DSTN | GSM4909285 | Human | Breast | IDC | 8.49e-25 | -2.95e-01 | 0.21 |
| 11034 | DSTN | GSM4909286 | Human | Breast | IDC | 2.62e-33 | -3.06e-01 | 0.1081 |
| 11034 | DSTN | GSM4909287 | Human | Breast | IDC | 1.29e-17 | -4.87e-01 | 0.2057 |
| 11034 | DSTN | GSM4909288 | Human | Breast | IDC | 1.11e-02 | -1.55e-01 | 0.0988 |
| 11034 | DSTN | GSM4909292 | Human | Breast | IDC | 1.05e-06 | 3.80e-01 | 0.1236 |
| 11034 | DSTN | GSM4909293 | Human | Breast | IDC | 2.22e-04 | -8.48e-02 | 0.1581 |
| 11034 | DSTN | GSM4909294 | Human | Breast | IDC | 4.61e-21 | 1.39e-01 | 0.2022 |
| 11034 | DSTN | GSM4909296 | Human | Breast | IDC | 2.55e-12 | -2.64e-01 | 0.1524 |
| 11034 | DSTN | GSM4909297 | Human | Breast | IDC | 2.40e-31 | -4.82e-01 | 0.1517 |
| 11034 | DSTN | GSM4909298 | Human | Breast | IDC | 2.09e-02 | 2.17e-01 | 0.1551 |
| 11034 | DSTN | GSM4909302 | Human | Breast | IDC | 2.19e-04 | -2.35e-01 | 0.1545 |
| 11034 | DSTN | GSM4909303 | Human | Breast | IDC | 5.32e-04 | 2.64e-01 | 0.0438 |
| 11034 | DSTN | GSM4909304 | Human | Breast | IDC | 2.27e-36 | -4.93e-01 | 0.1636 |
| 11034 | DSTN | GSM4909309 | Human | Breast | IDC | 2.35e-14 | -4.54e-01 | 0.0483 |
| 11034 | DSTN | GSM4909311 | Human | Breast | IDC | 8.64e-50 | -1.64e-01 | 0.1534 |
| 11034 | DSTN | GSM4909312 | Human | Breast | IDC | 5.46e-10 | 1.61e-01 | 0.1552 |
| 11034 | DSTN | GSM4909315 | Human | Breast | IDC | 4.35e-71 | 4.92e-01 | 0.21 |
| 11034 | DSTN | GSM4909316 | Human | Breast | IDC | 7.75e-32 | 4.13e-01 | 0.21 |
| 11034 | DSTN | GSM4909317 | Human | Breast | IDC | 9.12e-38 | 4.51e-01 | 0.1355 |
| 11034 | DSTN | GSM4909318 | Human | Breast | IDC | 2.33e-39 | 7.16e-01 | 0.2031 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003295626 | Oral cavity | EOLP | regulation of actin cytoskeleton organization | 84/2218 | 358/18723 | 4.24e-10 | 3.65e-08 | 84 |
| GO:190290525 | Oral cavity | EOLP | positive regulation of supramolecular fiber organization | 57/2218 | 209/18723 | 8.27e-10 | 6.12e-08 | 57 |
| GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
| GO:003253523 | Oral cavity | EOLP | regulation of cellular component size | 83/2218 | 383/18723 | 2.73e-08 | 1.12e-06 | 83 |
| GO:011005326 | Oral cavity | EOLP | regulation of actin filament organization | 65/2218 | 278/18723 | 4.55e-08 | 1.72e-06 | 65 |
| GO:005149524 | Oral cavity | EOLP | positive regulation of cytoskeleton organization | 55/2218 | 226/18723 | 1.19e-07 | 3.99e-06 | 55 |
| GO:000815424 | Oral cavity | EOLP | actin polymerization or depolymerization | 53/2218 | 218/18723 | 2.08e-07 | 6.55e-06 | 53 |
| GO:000806422 | Oral cavity | EOLP | regulation of actin polymerization or depolymerization | 47/2218 | 188/18723 | 4.19e-07 | 1.19e-05 | 47 |
| GO:003083222 | Oral cavity | EOLP | regulation of actin filament length | 47/2218 | 189/18723 | 4.95e-07 | 1.34e-05 | 47 |
| GO:003298421 | Oral cavity | EOLP | protein-containing complex disassembly | 48/2218 | 224/18723 | 3.01e-05 | 4.30e-04 | 48 |
| GO:004324411 | Oral cavity | EOLP | regulation of protein-containing complex disassembly | 24/2218 | 121/18723 | 7.53e-03 | 3.62e-02 | 24 |
| GO:00308347 | Oral cavity | EOLP | regulation of actin filament depolymerization | 13/2218 | 54/18723 | 9.03e-03 | 4.14e-02 | 13 |
| GO:190290318 | Prostate | BPH | regulation of supramolecular fiber organization | 133/3107 | 383/18723 | 2.40e-18 | 8.73e-16 | 133 |
| GO:000701518 | Prostate | BPH | actin filament organization | 147/3107 | 442/18723 | 3.36e-18 | 1.15e-15 | 147 |
| GO:003297018 | Prostate | BPH | regulation of actin filament-based process | 133/3107 | 397/18723 | 7.07e-17 | 1.62e-14 | 133 |
| GO:190290518 | Prostate | BPH | positive regulation of supramolecular fiber organization | 84/3107 | 209/18723 | 3.00e-16 | 5.63e-14 | 84 |
| GO:003295618 | Prostate | BPH | regulation of actin cytoskeleton organization | 118/3107 | 358/18723 | 1.51e-14 | 1.87e-12 | 118 |
| GO:005149516 | Prostate | BPH | positive regulation of cytoskeleton organization | 83/3107 | 226/18723 | 1.83e-13 | 1.86e-11 | 83 |
| GO:011005318 | Prostate | BPH | regulation of actin filament organization | 96/3107 | 278/18723 | 1.90e-13 | 1.89e-11 | 96 |
| GO:000815416 | Prostate | BPH | actin polymerization or depolymerization | 72/3107 | 218/18723 | 1.82e-09 | 7.59e-08 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DSTN | deletion | Frame_Shift_Del | novel | c.249delN | p.Leu84CysfsTer16 | p.L84Cfs*16 | P60981 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| DSTN | SNV | Missense_Mutation | c.385C>G | p.Gln129Glu | p.Q129E | P60981 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DSTN | SNV | Missense_Mutation | c.404G>T | p.Cys135Phe | p.C135F | P60981 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DSTN | SNV | Missense_Mutation | novel | c.272C>T | p.Thr91Ile | p.T91I | P60981 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DSTN | SNV | Missense_Mutation | c.349N>C | p.Tyr117His | p.Y117H | P60981 | protein_coding | deleterious(0) | possibly_damaging(0.822) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DSTN | SNV | Missense_Mutation | rs138670114 | c.61C>T | p.Arg21Cys | p.R21C | P60981 | protein_coding | tolerated(0.2) | benign(0.02) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.300_301insT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DSTN | deletion | Frame_Shift_Del | rs750962255 | c.301delN | p.Leu103CysfsTer6 | p.L103Cfs*6 | P60981 | protein_coding | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.308dupT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-DM-A1HA-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| DSTN | insertion | Frame_Shift_Ins | rs767965259 | c.300_301insT | p.Leu103PhefsTer12 | p.L103Ffs*12 | P60981 | protein_coding | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |